Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217899 · ClinicalTrials.gov registry record · Phase 2
Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony
A Phase 2 study of Blood Loss, Surgical and Blood Loss, Postoperative, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT07217899: Recruiting Phase 2 study of Blood Loss, Surgical and Blood Loss, Postoperative, sponsored by University of Michigan.
NCT07217899 is a Phase 2 study of Blood Loss, Surgical and Blood Loss, Postoperative that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 140 participants, above the 113-participant average among 6 other Blood Loss, Surgical trials with a reported enrollment target (24% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07217899, a Phase 2 study of Blood Loss, Surgical and Blood Loss, Postoperative, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is being done to learn what effect a single dose of calcium gluconate will have on blood loss at the time of cesarean delivery in pregnancy patients at high risk for uterine atony.
Primary Outcome
Standardized volumetric assessment of blood loss during cesarean section
Conditions Studied
Interventions
- OTHER Saline
- DRUG Calcium Gluconate
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT07217899 shows while recruiting
NCT07217899 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 113-participant average among 6 other Blood Loss, Surgical trials with a reported enrollment target (24% higher).
The record links to 3 conditions, with Blood Loss, Surgical appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT07217899 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07217899 about?
NCT07217899 is a clinical study titled "Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony". This research study is being done to learn what effect a single dose of calcium gluconate will have on blood loss at the time of cesarean delivery in pregnancy patients at high risk for uterine atony.
What is the current status of trial NCT07217899?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-10-20. Estimated completion is 2026-08.
What conditions does trial NCT07217899 study?
This clinical trial studies the following conditions: Blood Loss, Surgical, Blood Loss, Postoperative, Uterine Atony.
What interventions are being tested in trial NCT07217899?
The interventions under investigation include: Saline (OTHER), Calcium Gluconate (DRUG).
Who is sponsoring clinical trial NCT07217899?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217899 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Loss, Surgical
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
RECRUITING · Phase 4
-
Tranexamic Acid in Adult Spinal Deformity Surgery
RECRUITING · Phase 3
-
Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery
COMPLETED · Phase 3
-
PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
COMPLETED · Phase 4
-
Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery
COMPLETED · Phase 4
-
Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI